Naftidrofuryl
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C24H33NO3 |
| Molar mass | 383.524 g/mol |
|
WikiDoc Resources for Naftidrofuryl |
|
Articles |
|---|
|
Most recent articles on Naftidrofuryl Most cited articles on Naftidrofuryl |
|
Media |
|
Powerpoint slides on Naftidrofuryl |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Naftidrofuryl at Clinical Trials.gov Trial results on Naftidrofuryl Clinical Trials on Naftidrofuryl at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Naftidrofuryl NICE Guidance on Naftidrofuryl
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Naftidrofuryl Discussion groups on Naftidrofuryl Patient Handouts on Naftidrofuryl Directions to Hospitals Treating Naftidrofuryl Risk calculators and risk factors for Naftidrofuryl
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Naftidrofuryl |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Naftidrofuryl (INN, also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate) is a drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.[1] It may also be a 5-HT2 receptor antagonist. It is also licenced for the treatment of intermittent claudication due to peripheral arterial disease.
It is sold under the brand name Dusodril (Merck) and cerebromap for multiapex in middle east. It is also sold as Praxilene in the United Kingdom.[2]
Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[3]
Naftidrofuryl may be effective for relieving the pain of muscle cramps.[4]
References
- ↑ Reynolds, J.E.F. (ed.) (1993). Martindale: The extra pharmacopoeia (30th edition ed.). London: Pharmaceutical Press. p. 1310. ISBN 0-85369-300-5.
- ↑ http://www.patient.co.uk/medicine/naftidrofuryl
- ↑ http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
- ↑ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
- Pages with script errors
- CS1 maint: Extra text: authors list
- CS1 maint: Extra text
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Vasodilators
- Cardiovascular Drugs
- Drug